Proteomics & Protein Research

Myriad RBM has manufactured and validated immunoassays based on Quanterix's single molecule array technology, Simoa.

The MRM-MS-based method combines use of conventional stable isotope-labeled peptide standards with a series of endogenous protein standards.

DSysMap combines mutation information with protein interaction data to provide a clearer picture of functional changes associated with the development of complex diseases.

The group's effort looked at the development steps required for successful implementation of MRM-MS assays as well as promising technical advances.

The firm is now clinically validating a mass spec-based test for quantifying native insulin and its therapeutic analogs and another test for type 2 diabetes.